Figure 1 | Scientific Reports

Figure 1

From: Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema

Figure 1

Patient disposition. BCVA, best-corrected visual acuity; CRT, central retinal thickness; FAS, full analysis set; IVT-AFL, intravitreal aflibercept; SAS, safety analysis set. aPatients could have been excluded from the FAS for more than one reason. bPatients had follow-up data available to at least 23 months, with a visit, injection, BCVA assessment, or optical coherence tomography evaluation between 23 and 25 months from the first IVT-AFL injection.

Back to article page